Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- Check3 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4, indicating a newer build of the page's documentation or interface. This reflects an incremental deployment change to the page.SummaryDifference0.0%

- Check9 days agoChange DetectedTwo new sites were added: Malmö, Skåne County, Sweden, 205 02 and Taoyuan, Taiwan, 333; two existing entries were removed/renamed: Malmo, Skåne County, Sweden, 205 02 and Taoyuan District, Taiwan, 333. This update reflects the updated geographic identifiers for trial locations.SummaryDifference0.0%

- Check17 days agoChange DetectedResults have been posted for the study, including primary and secondary outcomes (e.g., RFS and OS definitions and time frames), adverse events, and quality-of-life measures. The update also references the Study Protocol and Statistical Analysis Plan and lists the results reporting dates.SummaryDifference1.0%

- Check24 days agoChange DetectedClinicalTrials.gov’s page revision/version label was updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.0%

- Check31 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check52 days agoChange DetectedThe Locations entry changed from Napoli, Italy, 80147 to Naples, Italy, 80147.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.